mertansine

Mertansine 是一种微管蛋白抑制剂，也是一种抗体可缀合的美登木素生物碱。Mertansine 对HCT-15和A431细胞的IC50分别是0.750和0.04nM。

Mertansine (GMP)是 Mertansine 的 GMP 级别试剂。Mertansine 是一种微管蛋白抑制剂，也是一种抗体可缀合的美登木素生物碱。Mertansine 对HCT-15和A431细胞的IC50分别是0.750和0.04nM。

Lorvotuzumab mertansine 是一种抗体偶联药物（ADC），可用于生命科学相关研究。其 CAS 号为 1008106-64-6。

Cantuzumab mertansine (SB-408075; huC242-DM1) 是一种ADC，是强效美登素衍生物 (DM1) 和针对 CanAg 的人源化单克隆抗体 (huC242) 的免疫偶联物。Cantuzumab mertansine 对结肠癌细胞具有细胞毒性，并且对一系列 CanAg 阳性人肿瘤异种移植物具有广泛的抗肿瘤活性。

DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate that combines the microtubulin inhibitor DM1 (mertansine), which is an antibody-conjugatable maytansinoid designed to reduce systemic toxicity and improve tumor-specific delivery, with the linker DBCO-PEG4-Ahx, for the development of antibody drug conjugates (ADCs).

DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for the development of antibody-drug conjugates (ADCs). This conjugation aims to mitigate the systemic toxicity associated with maytansine while improving tumor-specific delivery, leveraging DM1’s capabilities as an antibody-conjugatable maytansinoid.

SC-VC-PAB-DM1 is a drug-linker conjugate utilized in Antibody-Drug Conjugates (ADC), featuring DM1 (Mertansine, a tubulin inhibitor) linked through the SC-VC-PAB[1] ADC linker to deliver potent antitumor activity.

Lorvotuzumab (Anti-NCAM1 CD56 Reference Antibody (lorvotuzumab)) 是一种人源化结合 CD56 (NCAM1) 的单克隆抗体。Lorvotuzumab 可用于合成抗体-药物偶联物（ Lorvotuzumab mertansine）。

Cantuzumab 是一种靶向 CanAg 抗原的单克隆抗体，具有抗肿瘤活性，可用于合成ADC 化合物 cantuzumab mertansine。